This study is looking at whether an intravenous immunoglobulin (IVIG) called Panzyga can help people with small fiber neuropathy (SFN). SFN is a condition where the small nerves in your skin are damaged, which can cause pain. Panzyga is already approved for other conditions, but not yet for SFN. Researchers want to see if Panzyga can improve the density of nerve fibers in your skin, which will be measured through a skin biopsy. You may be able to join if you are at least 18 years old and have been diagnosed with SFN through a skin biopsy within the last year. The study aims to enroll 20 participants.

Study design

This is an interventional study, meaning participants will receive either Panzyga IVIG or a placebo. The study plans to enroll 20 participants.

What's involved

You would need to have a skin biopsy at the start of the study and again at Week 24 to measure nerve fiber density.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at Week 24, which suggests follow-up for at least 24 weeks after treatment begins.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.